Abstract:Ovarian cancer (OC) is an aggressive malignancy characterized by a complex immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy by reactivating the antitumor immune response suppressed by tumor cells. However, in the case of OC, these inhibitors have failed to demonstrate significant improvements in patient outcomes, and existing biomarkers have not yet identified promising subgroups. Consequently, there remains a pressing need to understand the interplay between OC tumor cells and their surrounding microenvironment to develop effective immunotherapeutic approaches. This review aims to provide an overview of the OC TME and explore its potential as a therapeutic strategy. Tumor-infiltrating lymphocytes (TILs) are major actors in OC TME. Evidence has been accumulating regarding the spontaneous TILS response against OC antigens. Activated T-helpers secrete a wide range of inflammatory cytokines with a supportive action on cytotoxic T-cells. Simultaneously, mature B-cells are recruited and play a significant antitumor role through opsonization of target antigens and T-cell recruitment. Macrophages also form an important subset of innate immunity (M1-macrophages) while participating in the immune-stimulation context. Finally, OC has shown to engage a significant natural-killer-cells immune response, exerting direct cytotoxicity without prior sensitization. Despite this initial cytotoxicity, OC cells develop various strategies to induce an immune-tolerant state. To this end, multiple immunosuppressive molecules are secreted to impair cytotoxic cells, recruit regulatory cells, alter antigen presentation, and effectively evade immune response. Consequently, OC TME is predominantly infiltrated by immunosuppressive cells such as FOXP3+ regulatory T-cells, M2-polarized macrophages and myeloid-derived suppressor cells. Despite this strong immunosuppressive state, PD-1/PD-L1 inhibitors have failed to improve outcomes. Beyond PD-1/PD-L1, OC expresses multiple other immune checkpoints that contribute to immune evasion, and each representing potential immune targets. Novel immunotherapies are attempting to overcome the immunosuppressive state and induce specific immune responses using antibodies adoptive cell therapy or vaccines. Overall, the OC TME presents both opportunities and obstacles. Immunotherapeutic approaches continue to show promise, and next-generation inhibitors offer exciting opportunities. However, tailoring therapies to individual immune characteristics will be critical for the success of these treatments.

Targeting tumor microenvironment in ovarian cancer: Premise and promise.

Harnessing Tumor Immunogenomics: Tumor Neoantigens in Ovarian Cancer and Beyond

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

Recent advances in understanding the immune microenvironment in ovarian cancer

Metabolic Cross-Talk Between Ovarian Cancer and the Tumor Microenvironment-Providing Potential Targets for Cancer Therapy.

Metabolic cross-talk between ovarian cancer and the tumor microenvironment-providing potential targets for cancer therapy

Revisiting Ovarian Cancer Microenvironment: a Friend or a Foe?

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy

Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy

Tumor Microenvironment: the Culprit for Ovarian Cancer Metastasis?

Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy

Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment

Aberrant angiogenic signaling pathways: Accomplices in ovarian cancer progression and treatment

The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors

Tumor Microenvironment: From Cervical Carcinogenesis to Therapeutic Advancements

New Developments in Molecular Targeted Therapy of Ovarian Cancer.

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential

Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment

Targeting the immune microenvironment for ovarian cancer therapy

Emerging targeted drug delivery strategies toward ovarian cancer